EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY-NC 4.0

Cardiovascular Challenges in Chronic Lymphocytic Leukemia ( CLL ) Patients Undergoing Bruton Tyrosine Kinase ( BTK ) Inhibitor Therapy

Stefano Oliva, Stefano Molica iD

European Journal of Haematology · 2026

DOI: 10.1111/ejh.70047 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift European Journal of Haematology, 2026. Verfasst von Stefano Oliva und 1 weiteren Autor:innen. Beteiligte Einrichtung: Cardio-Oncology Unit, IRCCS Istituto Tumori, "Giovanni Paolo II", Bari, Italy. Hauptthemen laut MEDLINE: Protein Kinase Inhibitors, Leukemia, Lymphocytic, Chronic, B-Cell, Agammaglobulinaemia Tyrosine Kinase, Cardiovascular Diseases. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives Bruton tyrosine kinase inhibitors (BTKis) have revolutionized treatment for chronic lymphocytic leukemia (CLL), but cardiovascular (CV) toxicities pose significant challenges. Second‐generation BTKis offer improved target specificity, yet CV risks persist. This expert opinion review evaluates current evidence and offers guidance for managing BTKi‐associated CV events, particularly in patients with comorbidities.

Methods

A hematologist, specialist in CLL, and a cardiologist with specific expertise in managing cardiac complications arising from oncologic therapies conducted a systematic literature review. Subsequently, clinical findings synthesized through multidisciplinary expert discussions led to the development of practical recommendations for CV risk stratification and management in patients with CLL receiving BTKi therapy.

Results

Regular CV monitoring is essential for early detection of atrial fibrillation (AF), hypertension, and ventricular arrhythmias. A multidisciplinary approach between hematologists and cardiologists is recommended for comprehensive care. Identifying hematological biomarkers for predicting cardiotoxicity and exploring cardioprotective therapies for high‐risk patients should be prioritized.

Conclusions

It is essential to educate healthcare providers about the CV risks associated with BTKis. Additionally, clinical guidelines should be regularly updated to reflect the latest evidence, ensuring effective prevention and management strategies. In patients with a heightened risk of CV complications, the use of second‐generation BTKis should be prioritized. Ongoing cardiovascular monitoring is also recommended to reduce the risk of adverse events and minimize treatment discontinuation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein Kinase InhibitorsLeukemia, Lymphocytic, Chronic, B-CellAgammaglobulinaemia Tyrosine KinaseCardiovascular DiseasesAntineoplastic AgentsHumansCardiotoxicityDisease Management

Stichwörter der Autor:innen

Bruton tyrosine kinase inhibitorsatrial fibrillationcardiovascular toxicitycardio‐oncologychronic lymphocytic leukemiaheart failurehypertensionrisk stratificationsecond‐generation BTK inhibitors

Substanzen

Protein Kinase InhibitorsAgammaglobulinaemia Tyrosine KinaseAntineoplastic Agents

Autor:innen und Institutionen

  • Cardio-Oncology Unit, IRCCS Istituto Tumori, "Giovanni Paolo II", Bari, Italy.
  • Department of Hematology, Hull University Teaching Hospitals NHS Trust, Hull, UK.

ORCID-Profile: Stefano Molica

Förderung

  • AstraZeneca

Zitieren

APA

Oliva, S., & Molica, S. (2026). Cardiovascular Challenges in Chronic Lymphocytic Leukemia ( CLL ) Patients Undergoing Bruton Tyrosine Kinase ( BTK ) Inhibitor Therapy. European Journal of Haematology. https://doi.org/10.1111/ejh.70047

Vancouver

Oliva S, Molica S. Cardiovascular Challenges in Chronic Lymphocytic Leukemia ( CLL ) Patients Undergoing Bruton Tyrosine Kinase ( BTK ) Inhibitor Therapy. European Journal of Haematology. 2026. doi:10.1111/ejh.70047

BibTeX
@article{Oliva2026,
  author = {Oliva, Stefano and Molica, Stefano},
  title = {Cardiovascular Challenges in Chronic Lymphocytic Leukemia ( CLL ) Patients Undergoing Bruton Tyrosine Kinase ( BTK ) Inhibitor Therapy},
  journal = {European Journal of Haematology},
  year = {2026},
  doi = {10.1111/ejh.70047}
}
Kostenlos starten →